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Abstract The immunomodulatory and anti-inflammatory
properties of bone marrow-derived mesenchymal stem cells
(BM-MSCs) have been considered as an appropriate candi-
date for treatment of autoimmune diseases. Previous studies
have revealed that treatment with BM-MSCs may modulate
immune responses and alleviate the symptoms in experimen-
tal autoimmune encephalomyelitis (EAE) mice, an animal
model of multiple sclerosis. Therefore, the present study was
designed to examine immunomodulatory effects of BM-
MSCs in the treatment of myelin oligodendrocyte glycopro-
tein (MOG) 35-55-induced EAE in C57BL/6 mice. MSCs
were obtained from the bonemarrow of C57BLmice, cultured
with DMEM/F12, and characterized with flow cytometry for
the presence of cell surface markers for BM-MSCs. Following
three passages, BM-MSCs were injected intraperitoneally into
EAE mice alone or in combination with rapamycin.
Immunological and histopathological effects of BM-MSCs
and addition of rapamycin to BM-MSCs were evaluated.
The results demonstrated that adding rapamycin to BM-
MSCs transplantation in EAE mice significantly reduced in-
flammation infiltration and demyelination, enhanced the im-
munomodulatory functions, and inhibited progress of neuro-
logical impairments compared to BM-MSC transplantation
and control groups. The immunological effects of rapamycin
and BM-MSC treatments were associated with the inhibition
of the Ag-specific lymphocyte proliferation, CD8+ cytolytic
activity, and the Th1-type cytokine (gamma-interferon
(IFN-γ)) and the increase of Th-2 cytokine (interleukin-4
(IL-4) and IL-10) production. Addition of rapamycin to BM-
MSCs was able to ameliorate neurological deficits and pro-
vide neuroprotective effects in EAE. This suggests the poten-
tial of rapamycin and BM-MSC combined therapy to play
neuroprotective roles in the treatment of neuroinflammatory
disorders.
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Introduction
Multiple sclerosis (MS) can be considered as an inflammatory
neurodegenerative disorder. Neuronal demyelination and ax-
onal injury play major roles in pathophysiology of MS [1, 2].
Experimental autoimmune encephalomyelitis (EAE) is an
organ-specific cell-mediated autoimmune demyelinating dis-
ease, characterized by neurological deficits and lymphocytic
andmononuclear cell infiltration of the central nervous system
(CNS) [3, 4]. A number of therapeutic strategies have been
studied in an attempt to minimize or ameliorate tissue damage
in EAE model. However, due to the complexity of EAE path-
ogenesis and the heterogeneity among patients, combination
therapy strategies that target a range of various disease mech-
anisms might be more efficient than monotherapy [5, 6].
Transplantation of bone marrow-derived mesenchymal
stem cells has been extensively studied in EAE experimental
animal model [7–9] based on their self-renewal capacity, the
ability to migrate into inflammation sites, potential of differ-
entiation into multiple lineages, and immunomodulatory and
neuroprotective properties [10–13]. Different immunomodu-
latory and neuroprotective mechanisms are involved in the
ameliorative effects of bone marrow-derived mesenchymal
stem cells (BM-MSCs) in the treatment of EAE [14]. It has
been emphasized that BM-MSCs require being primed by
inflammatory signals to induce their maximal immunosup-
pressive activities [15]. Previous studies have also demonstrat-
ed that BM-MSC immunosuppressive efficacy may be im-
proved through stimulation by toll-like receptor (TLR) ago-
nists [16] and gamma-interferon (IFN-γ) [17].
Rapamycin is a potent immunomodulator with fewer side
effects compared to other immunosuppressants, e.g., cyclo-
sporine [18]. Rapamycin has been used for a decade in trans-
plant patients to prevent graft rejection [19]. Rapamycin has
been reported to increase the percentage of regulatory T (Treg)
cells in vivo and promote immunomodulation [20–22].
Rapamycin selectively promotes expansion of functional hu-
man Tregs and depletes human CD4+ CD25− T effector cells
[23]. In EAE animal model, rapamycin was highly effective in
preventing the onset and severity of disease [21]. More recent-
ly, it has been shown that rapamycin can increase the immu-
nosuppressive activity of MSCs in vitro [24]. Furthermore,
mammalian target of rapamycin (mTOR) inhibition can ex-
tend the life span of MSCs [25]. Besides their role in cell
culture, it has been demonstrated that rapamycin pretreatment
can optimize the immunomodulatory potential of MSCs in a
murine model of acute graft-versus-host disease [26]. All to-
gether, these observations suggest that rapamycin has the po-
tential to improve therapeutic effects of BM-MSCs in the
treatment of EAE.
In this study, we investigated whether adding rapamycin to
BM-MSC transplantation could augment their therapeutic and
immunomodulatory effects in EAE mice. As a result, we
demonstrate that the combination treatment additively amelio-
rated EAE in mice by reducing disease severity, CNS inflam-
mation, and demyelination compared to BM-MSC treatment
alone. Moreover, this combination therapy enhanced immu-
nomodulatory properties, suggesting the potential of combi-
nation therapy to improve the recovery of patients with MS.
Materials and Methods
Reagents
Roswell ParkMemorial Institute (RPMI) cell culture medium,
penicillin/streptomycin, and fetal bovine serum (FBS) were
purchased from Gibco (Invitrogen, Germany). Hooke kit for
EAE induction [myelin oligodendrocyte glycoprotein (MOG)
35–55/complete Freund’s adjuvant (CFA) emulsion and per-
tussis toxin (PTX):5×] and MOG 35–55 for in vitro stimula-
tion of cells were purchased from Hooke Laboratories (Hooke
Laboratories, EK-0115, Lawrence, MA, USA). Rapamycin
(Sigma-Aldrich, St. Louis, MO) was dissolved in a vehicle
solution of phosphate buffer containing DMSO 1/500.
Reagents required for histopathological analysis, including
paraffin, xylol, alcohol, phosphate buffer saline (PBS),
hematoxylin/eosin (H&E), and luxol fast blue (LFB) solution,
were obtained from Sigma (Sigma-Aldrich, Germany).
Cytokine ELISA kits were obtained from eBioscience
(eBioscience, San Diego, CA).
Animals
C57BL/6 female mice (n=10, 8–10 weeks old) were pur-
chased from Pasture Institute, Tehran, Iran. The animals were
housed in a pathogen-free animal condition with standard hu-
midity and 22–23 °C temperature and 12/12 (7–19) dark/light
cycle. Four animals were housed in each cage and maintained
1 week for acclimatization and then weighted once a week
during the experiment. All the experiments were approved
by the Ethical Committee of Golestan University of Medical
Sciences, Gorgan, Iran.
Murine Bone Marrow Mesenchymal Cell Extraction
and Culture Expansion
BM-MSCs were isolated from C57BL/6 mice (6–8 weeks
old) and collected by marrow aspiration of the shafts of
femurs and tibias into DMEM/F12 (Gibco, BRL,
Eggenstein, Germany) supplemented with 10 % FBS using
a 21-G needle. The cells were then washed in PBS and
centrifuged at 400×g for 5 min. The cells were seeded onto
25-cm2 flasks containing DMEM/F12 medium supplement-
ed with 10 % FBS, 100 U/ml penicillin/streptomycin
(Gibco, BRL, Eggenstein, Germany), and 2.5 μg/ml
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fungizone (Invitrogen, Paisley, Scotland). Culture medium
was changed at day 2 to remove non-adherent cells. Whole
medium was subsequently replaced weekly. The cells were
grown for 2–3 weeks until almost confluent. Adherent cells
were then detached by 0.25 % trypsin-EDTA and replated
using a 1:3 dilution until third passage.
BM-MSC Surface Marker Analysis
The expressions of surface antigens CD29, CD166, CD90,
CD44, CD73, and CD105 (as positive markers) and CD45,
CD34, and CD14 (as negative markers) on BM-MSCs were
evaluated by flow cytometry using the following monoclonal
antibodies: fluorescein isothiocyanate (FITC)-labeled anti-
CD45 (50 μg/ml), anti-CD44 (50 μg/ml), anti-CD90 (50 μg/
ml), and anti-CD105 (50 μg/ml) and phycoerythrin (PE)-la-
beled anti-CD14 (25 μg/ml), anti-CD34 (25 μg/ml), anti-
CD29 (20 μg/ml), anti-CD73 (20 μg/ml), and anti-CD166
(50 μg/ml; all from BD Biosciences, USA). The passage 3
of BM-MSCs was used for analysis of cell determinant
markers. Briefly, cells were incubated with the specific anti-
bodies or isotype control antibodies with 3 % bovine serum
albumin (Sigma, USA) in PBS for 30min at 4 °C, followed by
fixation with paraformaldehyde 1 % (Sigma, USA). Final
analysis was performed using flow cytometry (Partec PAS
III, Germany). CellQuest software was used for data analysis
(FCS EXPRESS).
Osteogenic and Adipogenic Differentiation Assays
The potency of BM-MSCs for differentiation to adipogenic
and osteogenic lineages was assessed as previously described
[27]. Briefly, adipogenic differentiation was induced by
adding 1-methyl-3-isobutylxanthine (0.5 mmol/l), dexameth-
asone (1 mol/l), insulin (10 g/ml), and indomethacin (0.2 mol/
l; all from Sigma-Aldrich) to subconfluent cultures of BM-
MSCs. Differentiation medium was changed each 3 days till
21 days. Adipogenesis was confirmed after 21 days and byOil
Red O staining and the accumulation of neutral lipids in fat
vacuoles. For osteogenic differentiation, cells were plated in
6-well culture plates at 3×103 cells/cm2 in BM-MSCmedium
supplemented with dexamethasone (0.1 mol/l), ascorbic acid
(0.05 mmol/l), and glycerophosphate (10 mmol/l). Matrix
mineralization was confirmed by calcium phosphate deposits
after 0.2 % Alizarin Red S (2% aqueous solution, pH 4.1–4.3,
adjusted with ammonium hydroxide) staining for 20 min.
EAE Induction
C57BL/6 female mice were immunized with Hooke kits
(Hooke Laboratories, EK-0115, Lawrence, MA, USA) ac-
cording to the manufacturer’s instructions. Briefly, after a mild
anesthesia, EAEmice received a subcutaneous injection in the
upper and lower back of MOG 35–55 (200 μg) peptide emul-
sified in CFA containing 400 μgMycobacterium tuberculosis.
Two hours later, and again 24 h thereafter, the mice received
an intraperitoneal injection of PTX (0.1 ml/animal/day).
Clinical Scoring of Disease and Disability
One week after the injection, the mice were examined daily
for development of disabilities. Most of the EAE mice dem-
onstrated clinical symptoms after approximately 10 days post-
injection. Mice that developed no clinical symptoms were
excluded. Clinical scores were blindly registered according
to standard protocol: 0, no disease; 1, floppy tail; 2, hind limb
weakness; 3, partial hind limb paralysis; 4, complete hind limb
paralysis; and 5, moribund stage [28]. Following the appear-
ance of EAE symptoms, mice were scored for disease severity
and categorized into separate test groups to obtain equally
weighted average disease scores before experimental
interventions.
BM-MSC and Rapamycin Treatments
The ability of combined treatment BM-MSCs/rapamycin to
reduce the symptoms of EAEwas examined by administration
of these treatments into EAE mice via intraperitoneal route.
Ten days post-EAE induction, animals were blindly divided
into three groups (n= 10), including (1) PBS (EAE-PBS)
group, (2) BM-MSC (EAE-BM-MSC) group (twice with
2 × 106 BM-MSC injections at days 10 and 17 after EAE
induction), and (3) combination of BM-MSC-rapamycin
(EAE-BM-MSC/rapamycin) group. For combination group,
rapamycin (0.3 mg/kg) was administered in 0.1 ml distilled
water once daily for 7 days beginning on day 10 post-EAE
induction in combination with 2×106 BM-MSCs two times at
10 and 17 after EAE induction. We evaluated the neurological
functions of EAE mice treated daily until 50-day post-MOG
injection.
Histopathological Studies
At the end of the follow-up period (50-day post-EAE in-
duction), five mice per group were anesthetized with keta-
mine (IP, 50 mg/kg) and xylezine (4 mg/kg). Thereafter,
mice were perfused with PBS containing 4 % paraformal-
dehyde (PFA). Spinal cord sections (L1 to L3) were dis-
sected and immersed in 4 % PFA overnight and then em-
bedded in paraffin. Finally, coronal sections were obtained
in 5-μm thickness. The quantification of neurological dam-
age in EAE mice was performed via histological analysis
of 5-μm paraffin CNS sections of EAE-PBS-, EAE-BM-
MSC-, and EAE-BM-MSC/rapamycin-treated groups.
Paraffin sections were stained with LFB to assess myelin
damage and with H&E to assess infiltrating cells. The
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sections were observed with an Olympus light microscope
(BX51, Olympus, Japan) and photographed with an
Olympus digital camera (Olympus, Japan) linked to a
microscope.
ImageJ software was used to calculate the extent of demy-
elination in the spinal cord as the percentage of volume frac-
tion in damage tissue/total area for 16 sections in each animal
(n=5). Furthermore, H&E staining was performed to study
infiltration of hematogenous cells into all the parts of CNS
[29]. The numbers of perivascular inflammatory infiltrates
were calculated and expressed as the numbers of inflammato-
ry infiltrates per square millimeter.
MOG-Specific Lymphocyte Proliferation Assay
Single-cell suspension of mononuclear cells was isolated
individually from the spleen of each mouse (n= 3) at
1 week after the last treatment, suspended to 5×105/ml
with RPMI complete medium (RPMI 1640 containing
10 % FCS, 2 mM L-glutamine, 1 % HEPES, 50 μM β-
mercaptoethanol, 200 U/ml penicillin, 200 μg/ml strepto-
mycin, and 100 U/ml of mycostatin) and seeded in 96-
well flat-bottom plates. Each cell sample was plated in
triplicate for each mouse. The culture was stimulated with
10 μM MOG 35–55 peptide, 2 μg/ml phytohemagglutinin
(PHA; Sigma Chemicals) as a positive control, bovine
serum albumin (BSA) as an irrelevant control, and medi-
um as a negative control. After incubation for 3 days at
37 °C with 5 % CO2, the proliferation responses were
detected by a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT; 5 mg/ml, Sigma) meth-
od. Dimethyl sulfoxide (DMSO; 100 μl) was added to
dissolve produced formazan crystals. Plates were read at
540 nm, and the results were expressed as stimulation
index (SI). The SI was determined as follows: OD values
of stimulated cells (Cs) minus relative cell numbers of
unstimulated cells (Cu) by relative OD values of
unstimulated cells [30].
SI = (Cs _ Cu)/Cu
Cell Cytotoxicity Assay
One week after the final treatment, mice (n = 3) were
sacrificed and their splenocytes were isolated. For each sam-
ple obtained from individual mouse, single-cell suspension of
mononuclear cells (used as the effector cells) was cocultured
in RPMI 1640 medium with washed target cells EL4 at 50:1
effector-to-target cell (E/T) ratios, in whichmaximal release of
LDH was observed. For preparation of the target cells, EL4
cells were stimulated with 10-μM MOG 35–55 peptide and
then incubated for 4 h.
After centrifugation, the supernatants (50 μl/well) were
transferred to the 96-well flat-bottom plates, and cytotoxic T
lymphocyte (CTL) activity was determined bymeasuring LDH
release using Cytotoxicity Detection Kit (LDH) according to
the procedures stated by the manufacturer (TaKaRa Company).
Several controls were used for the cytotoxicity assay.
BHigh control^ was the total LDH released from the target
cells, and all EL4 cells were lysed by medium containing 1 %
Triton X-100. BLow control^ was the natural release of LDH
from the target cells, which was obtained by adding EL4 cells
only in the assay medium. BT cell control^ that was used to
measure the natural release of LDH from T cells was obtained
by adding the different ratios of T cells only in the assay
medium. The assay for all samples, including the controls,
was performed in triplicates.
The LDH-mediated conversion of the tetrazolium salt into
red formazan product was measured at 490 nm after incuba-
tion at room temperature for 30 min [31]. The percentage of
specific cytolysis was determined by the following formula:
% Cytotoxity ¼ experimental value − effector cell controlð Þ− low control
high control−low control
 
 100
Spleen Cytokine Assay
Mononuclear cells from spleens of treated mice (n=3) were
prepared and incubated with RPMI-1640 at a concentration of
5×105 cells/well in 96-well plates (Nunk/Denmark) for 2 days.
The RPMIwas supplemented with 10%FCS, 1%L-glutamine,
1 %HEPES, 0.1 % 2ME, and 0.1 % penicillin/streptomycin and
pulsed with 2 μg/ml PHA or 10 μMMOG 35–55 peptide after
3 days. Cell-free supernatants were harvested and assayed for
interleukin-4 (IL-4), interleukin-10 (IL-10), and IFN-γ at 48 h
using a sandwich-based ELISA kit (eBioscience, USA) and per-
formed according to the manufacturer’s protocol. All studies
were performed in triplicate for each mouse.
Fig. 1 Characterization of bone marrow stem cells (BM-MSCs). BM-
MSC differentiation to adipogenic and osteogenic. a Adipogenic differ-
entiation was determined by Oil Red O staining for lipid vacuoles. b
Differentiation into osteocytes after induction culture was assessed by
Alizarin Red staining for calcium mineralization. c BM-MSC phenotype
identification by flow cytometry. Dot plots represent the surface markers
of BM-MSCs. The samples were analyzed using flow cytometry during
the third passage, evaluating the cell surface markers CD90, CD44,
CD105, CD73, CD29, CD166, CD34, CD45, and CD14. Gates were
set using isotype controls
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Statistical Analysis
Statistical analysis was performed using the SPSS 15 soft-
ware. Statistical analysis for significant differences on clin-
ical scores was performed with the non-parametric Mann–
Whitney U test for the clinical course of EAE. Lymphocyte
proliferation, CTL, and cytokine assay were analyzed by a
one-way ANOVA. Data are presented as mean ± SD.
Differences were considered statistically significant when
the P value was less than 0.05.
Results
BM-MSC Preparation and Characterization
BM-MSCs were successfully isolated from C57BL/6 mice
bone marrow. A homogeneous BM-MSC population was ob-
tained from C57BL/6 mice after three passages ex vivo. To
validate the multipotentiality of the BM-MSC cultures, in
vitro differentiation was induced into adipogenic and osteo-
genic lineages under culture conditions. The results showed
that BM-MSCs were able to differentiate into adipocytes and
osteocytes, confirming that the expanded cells are of BM-
MSC origin. Adipogenesis was evident by formation of lipid
droplets and transformation of BM-MSCs into round cells
following Oil Red O staining; approximately 55–60 % of
the cells appeared to be involved in adipoblast differentiation
(Fig. 1a). Osteogenesis was indicated by the formation of
Alizarin Red-positive calcified deposits, so about 70 % of
the cells showed differentiation to osteoblast (Fig. 1b).
Based on the adherent properties of BM-MSCs, the cells
were extracted from the femurs and tibias and characterized by
flow cytometry by the expression of common stem cell sur-
face markers. After the third passage, the majority of BM-
MSCs expressed the mesenchymal cell surface markers, lym-
phocyte differentiation marker CD73 (96.08 %; integral unit),
CD29 (95.46 %; Thy-1), and CD90 (95.06 %); activated leu-
kocyte cell adhesion molecule CD166 (81.08 %); and early
adhesion and hyaluronan markers CD44 (83.26 %) and
CD105 (49.41 %). The majority of BM-MSCs were negative
for CD45, a hematopoietic cell surface marker; CD34
(0.05 %); and CD14 (0.32 %, Fig. 1c). The data reported are
representative of three independent experiments, each per-
formed in duplicates.
Rapamycin Enhanced BM-MSC Improvement
of the Clinical Score
In order to assess the additive effect of rapamycin to BM-
MSCs on EAE progression, PBS, BM-MSCs, or a combina-
tion of BM-MSCs/rapamycin were administered intraperito-
neally in C57BL/6 mice 10 days after MOG immunization
(n= 10 mice/group). The mice were monitored to day 50
(50-day post-EAE induction). As presented in Fig. 2, the cu-
mulative scores and severity of EAE were ameliorated in
EAE-BM-MSCs (1.75 ± 0.11, 0 % mortality, P ≤ 0.001,
Mann–Whitney U test) and EAE-BM-MSC/rapamycin
groups (1.09 ± 0.16, 0 % mortality, P ≤ 0.001, Mann–
Whitney U test) compared to EAE-PBS mice (2.93±0.23,
40 % mortality). Additionally, treatment with the combination
of BM-MSCs-rapamycin caused a significant reduction in the
mean clinical scores compared to BM-MSCs alone (P≤0.01,
Mann–Whitney U test).
Rapamycin Improved BM-MSCEffects on Demyelination
and Inflammation
The clinical scores of the disease were recorded for 50 days,
and then, the mice were sacrificed and their spinal cords and
brains were harvested. Tissue samples were processed and
stained with H&E (Fig. 3a) and LFB (Fig. 3b) to assess for
the presence of inflammatory foci and demyelination. Cell
infiltration analysis of brains obtained from EAE-BM-MSC
mice on day 50 post-EAE induction revealed a significant
reduction in the total number of the inflammatory infiltrates
of mononuclear cells (44.1 ± 2.31) compared to EAE-PBS
mice (73.1 ± 6.3 cells per field, P ≤ 0.01, post hoc).
Combined administration of BM-MSC and rapamycin signif-
icantly decreased the number of infiltrating cells present in the
brain compared to the EAE-PBS and the EAE-BM-MSCmice
(25.4±2.6 cells per field, P≤0.001, post hoc; Fig. 3c).
Quantification of demyelination by density analysis of
LFB-stained spinal cord sections obtained from EAE-PBS
mice demonstrated a significant decrease in the myelinated
area compared to EAE-BM-MSC mice. EAE-BM-MSC/
rapamycin mice had a significant reduction in the demyelin-
ation compared to the EAE-PBS and the EAE-BM-MSCmice
(P≤0.05, post hoc).
Rapamycin Decreased BM-MSC Response on T Cell
Proliferation
The immunomodulatory effects of BM-MSCs represent an im-
portant mechanism by which these cells can induce protection
in EAE model. To determine whether the combined treatment
with BM-MSCs/rapamycin influenced the cell-mediated re-
sponse, we performed MOG-specific lymphocyte proliferation
in vitro. Splenocytes were isolated from treated mice and di-
vided into four parts stimulated with MOG antigen, PHA as a
positive control, BSA as an irrelevant control, and medium as a
negative control. As shown in Fig. 4, the lymphocyte prolifer-
ation rate was significantly lower in EAE-BM-MSCs/
rapamycin and EAE-BM-MSC mice compared to EAE-PBS
mice (P≤0.001). Furthermore, the combined group had a less
significant lymphocyte proliferation response than EAE-BM-
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MSC group (P≤0.01). These results suggest that CD4 lympho-
cytes from EAE-BM-MSC/rapamycin mice exhibited a lower
proliferation response.
Rapamycin Augmented BM-MSC Anti-Inflammatory
Effect
Cellular immune response was evaluated by cytokine secre-
tion assay of the in vitro stimulated splenocytes. The Th1/Th2
cytokine ratio is a key regulator of clinical EAE disease.
IFN-γ secretion is a marker of Th1-type antigen-specific cel-
lular immune responses, while IL-4 and IL-10 are recognized
as Th2-type humoral-mediated immune response. The cyto-
kine profiles induced by combined treatment were investigat-
ed following stimulation with MOG antigen. As shown in
Fig. 5a, EAE-BM-MSCs/rapamycin and EAE-BM-MSCs
mice significantly generated less IFN-γ than EAE-PBS mice
(P≤0.001). IL-4 and IL-10 levels were significantly increased
when the combination of BM-MSCs/rapamycin or BM-MSCs
alone was administered compared to PBS group (P≤0.001;
Fig. 5b, c). Furthermore, stimulated IFN-γ production was
higher in the BM-MSC group compared to BM-MSCs/
rapamycin (P ≤ 0.001). BM-MSC/rapamycin treatment
produced significant higher level of IL-10 compared to
EAE-BM-MSC mice (P≤0.001). However, there was no sig-
nificant difference in the levels of IL-4 between EAE-BM-
MSC/rapamycin and EAE-BM-MSC groups. These results
suggest that splenocytes of EAE-BM-MSC/rapamycin mice
had a lower ratio of Th1/Th2 compared to BM-MSC and PBS
mice.
Rapamycin Reduced BM-MSC Effects on the CTL
Response
Several evidences have emphasized the contribution of CD8 T
cells in animal models of CNS autoimmunity. In our study, the
CTL response in immunized mice was examined using the
LDH release assay. The effector:target cell ratio up to the
maximum ratio of 100:1 was used in the present study. As
shown in Fig. 6, the cytolytic activity was significantly higher
in mice treated with the PBS than in those treated with the
combined treatment of BM-MSCs/rapamycin or BM-MSCs
alone (P<0.001). Furthermore, BM-MSC group had a signif-
icantly higher antigen-specific CTL response than the group
treated with the combined treatment (P≤0.01).
Fig. 2 The combination of BM-MSC/rapamycin attenuates clinical EAE
severity in mice. a During 50-day clinical follow-up, the disease severity
of C57BL/6-EAE in mice transplanted with combination of BM-MSC/
rapamycin was significantly reduced compared to EAE-BM-MSC and
EAE-PBS mice. Data are expressed as the mean clinical score of all the
mice in the group versus the time post-MOG injection. b Cumulative
scores (CSs) were calculated as the sum of all EAE clinical scores
(mean ± SD, n= 7) from disease onset to day 50 post-challenge, divided
by the number of mice in each group. Development of EAE was signif-
icantly reduced in combined treated mice (P< 0.001). Graphs represent
the combination of all independent experiments. Clinical severity of EAE
was graded by the widely used scale ranging from 0 to 5. Data are
expressed as the mean ± SD. ** and *** indicate significance at
P ≤ 0.01 and P ≤ 0.001, respectively
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Discussion
MS, an inflammatory disease of the CNS, is characterized by
an autoimmune response against myelin proteins, which re-
sults in progressive neurological dysfunction [32]. The avail-
able immunomodulatory treatments, such as beta-interferon,
are only partially effective, and more effective treatment strat-
egies to reduce the chronic and progressive aspects of the
disease are needed [6]. Considering the complex pathophysi-
ology of MS, combination therapy offers an advantage over
monotherapy. Combined therapy is considered to be most
effective when the two immunomodulatory agents affect dif-
ferent mechanisms of action and alleviate adverse events by
using lower doses of individual medications [5, 33]. Among
the compounds with potent immunosuppressive activity
aimed at inducing immunomodulation and redirecting im-
mune responses are mesenchymal stem cells and rapamycin.
Rapamycin inhibits the mammalian target of rapamycin path-
way, which is downstream of costimulatory molecules (such
as CD28) and cytokine receptors [34]. Rapamycin, also
known as sirolimus, is a macrocyclic triene anti-biotic
displaying immunomodulatory activity. It has been widely
used in preventing allogenic transplant rejection and in
treating some autoimmune diseases [22]. A therapeutic role
of rapamycin has already been suggested in several animal
models of autoimmune diseases, such as EAE [22], autoim-
mune arthritis [35], and the non-obese diabetic [36] mice. The
animal studies suggest that the beneficial effects of rapamycin
Fig. 3 The combination of BM-MSC/rapamycin decreases
demyelination and inflammation outcomes of EAE mice. H&E (a) and
LFB (b) staining were performed to assess the extent of demyelination
andmononuclear cell infiltration in the CNS of EAEmice. In H&E panel,
arrows show the inflammatory cells. In LFB panel, the blue areas show
intact region (in normal group), whereas the pink areas show
demyelinating region. c Graphs representing the number of infiltrates
(n = 3 mice, from two independent experiments). Comparisons of the
H&E images show a decrease in the number of inflammatory cells in
the brain after administration of combined treatment compared with
BM-MSC and PBS groups (in EAE group, ***P ≤ 0.001). d Graphs
representing the quantification of demyelination by density analysis of
LFB-stained spinal cord sections obtained from combined EAE-BM-
MSC/rapamycin treatment demonstrated a significant increase in the my-
elinated area as compared to EAE-PBS mice (*P ≤ 0.05)
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are associated with its regulatory properties on T cell activa-
tion and proliferation [22]. Despite its significant advantages,
the previous studies suggested that high-dose rapamycin can
potently induce cell death [32]. Systemic administration of
rapamycin showed specific adverse events including revers-
ible cytopenia that seems to be dose dependent [26].
Therefore, a suboptimal dose of rapamycin was chosen for
use in our study.
It has been shown that administration of suboptimal doses
of rapamycin is not sufficient for the suppression of immune
responses [37]. Thus, the additive effect of 0.3 mg/kg
rapamycin to BM-MSCs was used to suppress EAE in this
study, and it was investigated whether the combination of a
two BM-MSCs and repeated administration of rapamycin at
suboptimal doses were capable of modulating immune re-
sponses and ameliorating EAE severity.
The present study shows that although BM-MSC trans-
plantation alone had significant effects on EAE mice com-
pared to the control animals, the additive effect of rapamycin
further protected EAE mice by reduction of clinical severity,
inflammatory infiltration, and demyelination as well as by
enhancement of the immunomodulatory responses.
These findings indicate that the therapeutic effect of com-
bined treatment on the clinical and histopathological features
of EAE is likely immune mediated. Improvement of the clin-
ical score was accompanied with a reduction in demyelinating
and inflammation areas in the CNS. This was established by
decreased IFN-γ secretion, splenocyte proliferation, and CD8
cytolytic activity stimulated by MOG 35–55 peptide in the
combined treatment group. Our study also revealed that the
additive effect of rapamycin on BM-MSCs significantly in-
creased the production of IL-4 and IL-10 and polarized the
cytokine profile toward Th2.
In keeping with our results, previous investigations re-
vealed that the activation of myelin-specific CD4 T cells is
critical to the pathogenesis of EAE. Those cells expressing
Th1-type cytokines, including IFN-γ and TNF-α, are required
for clinical severity of EAE, whereas Th2-type cytokines, in-
cluding IL-4, IL-10, and TGF-β, are protective [38, 39].
IFN-γ responses to myelin basic protein-derived peptides
and shifting the cytokine pattern ofmyelin-autoreactive Tcells
to a Th1 profile correlate with clinical disease progression
[40].
In our study, combined application of rapamycin and BM-
MSCs was associated with the inhibition of the CD8+ cyto-
lytic activity. While much emphasis had been focused on the
role of CD4+ T cells in MS, recent evidence have proposed
that CD8+ T lymphocytes might also have a role in this dis-
ease. Huseby et al. have shown that CD8 T cell clones, spe-
cific for the class I-restricted fragment of myelin basic protein,
induce severe EAE with paralysis and other neurological def-
icits [41]. Furthermore, the increased number of CD8+ T cells
within the inflammatory brain lesions and oligoclonal expan-
sions of CD8+ T cells in the brain and cerebrospinal fluid of
MS patients support the pathogenic role of CD8+ T in MS
[42]. It has been shown that significant increases of CD8+ T
cells are generated upon immunization with MOG 35–55 in
C57BL/6 mice [43].
Several studies have confirmed the immunosuppressive
characteristics of BM-MSCs. It has been shown that BM-
MSCs can modulate the functions of both T and B lympho-
cytes. BM-MSCs can inhibit the production of IFN-γ by
CD4+ T and CD8+ T cells, whereas they can restore the
secretion of IL-4 by CD4+ and CD8+ T cells [44].
Therefore, the immunomodulatory features of BM-MSCs,
together with their capacity to differentiate into neuronal lin-
eages, support the neuroprotective effects of BM-MSCs in
EAE and suggest the potential therapeutic role in
neuroinflammatory disorders [45]. The present study comple-
ments these findings by demonstrating that BM-MSCs gen-
erate a more efficient effect on clinical severity of EAE, anti-
inflammatory, and neuroprotective activities when combined
with suboptimal doses of rapamycin. This may be partially
due to the enhanced additive clinical and immunological ef-
fects. The findings are in accordance with previous results
showing that a low concentration of rapamycin can attain
enhanced immunoregulatory potential of MSCs [24]. In this
regard, MSCs and rapamycin have both been reported to
increase the proportion of Tregs through direct [46].
Fig. 4 The combination of BM-MSC/rapamycin diminishes T cell
proliferation. Splenocyte proliferation levels after in vitro stimulation
with MOG35–55 peptide.C57BL/6 mice were immunized by MOG
35–55. After 10 days, the mice were treated IP with BM-MSC/
rapamycin and BM-MSCs (test groups) and PBS (negative control
groups). One week after final treatment, spleens of individual mice
(n = 3) were removed and lymphocyte proliferation was evaluated with
MTT method. Formazan crystal formation after incubation of MTT was
determined by solving the crystals in DMSO, and optical density (OD)
was read at 540 nm. All tests were performed in triplicate for each mouse.
Values are the mean ± SD of the mean for the experiments. Lymphocyte
proliferation of the EAE-PBS group was significantly higher than those in
EAE-BM-MSC and EAE-BM-MSC/rapamycin groups (P< 0.001). ***
indicates statistically significant difference between the marked groups as
determined by one-way ANOVA
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In agreement with our synergistic effect findings, it has
been reported that MSCs combined with low-dose rapamycin
exerted immunosuppressive effects via cell-cell contact and
the regulation of cytokine secretion and significantly
prolonged allograft survival in the diabetic mice. The study
presented that MSCs combined with rapamycin downregulat-
ed IL-2 and IFN-γ expressions and modulate T cell pheno-
types toward Th1 suppression compared with the rapamycin
group [47]. Kim et al. findings represented that rapamycin
pretreatment of MSCs in a murine model of acute graft-
versus-host disease (aGVHD) were associated with a reduc-
tion of Th17 cells and an increase in regulatory T cells [26].
Synergism has also been stated with systemic administration
of rapamycin together with MSCs in a heart transplant mode
[48].
The suppressive effects of MSCs and rapamycin were also
seen to be additive in vitro. Kim et al. have shown that
rapamycin can induce autophagy of MSCs while preserving
the expression of surface markers and multilineage differenti-
ation potentials of MSCs under in vitro conditions. That may
underlie the effective immunomodulatory effect of MSCs by
rapamycin treatment [26]. B7-H1, also known as CD274 or
programmed cell death 1 ligand (PD-L1), has been reported
for a synergistic interaction of MSCs and RAPA in the sup-
pression of immune responses [49].
Several studies have verified that MSCs combined with
other immunosuppressive drugs induce allograft immune tol-
erance through immunosuppression in vivo. Hou et al. has
exhibited that a treatment with combined treatment with a
low dose of minocycline and mesenchymal stem cells
exceeded the effects of either treatment alone and exerted
synergistic therapeutic effects on EAE progression [50].
Consequently, the additive effect of rapamycin on BM-MSC
protective function meets potent immunosuppressive and pro-
tective effects in current investigation and characteristically
protecting and inhibiting EAE development, thus rationale
for testing these medications in combination therapy.
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